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Background: Selective reporting bias (SRB), the incomplete publication of outcomes measured or of analyses
performed in a study, may lead to the over- or underestimation of treatment effects or harms. Cochrane systematic
reviews of interventions are required to assess the risk of SRB, achieved in part by applying the Cochrane risk of bias
tool to each included randomised trial. The Cochrane Handbook outlines strategies for a comprehensive risk of bias
assessment, but the extent to which these are followed by Cochrane review groups (CRGs) has not been assessed
to date. The objective of this study was to determine the methods which CRGs require of their authors to address
SRB within systematic reviews, and how SRB risk assessments are verified.
Methods: A cross-sectional survey was developed and distributed electronically to the 52 CRGs involved in
intervention reviews.
Results: Responses from 42 CRGs show that the majority refer their authors to the Cochrane Handbook for specific
instruction regarding assessments of SRB. The handbook strategies remain variably enforced, with 57 % (24/42) of
CRGs not requiring review authors to search for included trial protocols and 31 % (13/42) not requiring that contact
with individual study authors be attempted. Only half (48 %, 20/42) of the groups consistently verify review authors’
assessments of the risk of SRB to ensure completeness.
Conclusions: A range of practices are used by CRGs for addressing SRB, with many steps outlined in the Cochrane
Handbook being encouraged but not required. The majority of CRGs do not consider their review authors to be
sufficiently competent to assess for SRB, yet risk of bias assessments are not always verified by editors before
publication. The implications of SRB may not be fully appreciated by all CRGs, and resolving the identified issues
may require an approach targeting several steps in the systematic review process.
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Selective reporting bias (SRB) is a form of reporting bias
in which certain components of conducted research are
not fully presented based on the nature or direction of
the results [1]. SRB may include the incomplete publica-
tion of a study analysis (e.g. subgroup), inconsistencies
in predefined measurement scales or time-points for
data collection, or the re-ranking of outcomes previously
defined as primary or secondary [1–5]. A major compo-
nent of SRB is outcome reporting bias (ORB), which* Correspondence: emma.reid@vch.ca
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creativecommons.org/publicdomain/zero/1.0/occurs when only a subset of outcomes originally mea-
sured in a study is selected for publication [2, 3].
An analysis of randomised controlled trials (RCTs)
demonstrated that 40–62 % of trials had changed, omit-
ted or introduced one or more primary outcomes for
publication, indicating a high prevalence of SRB [3].
There is also evidence to suggest that study outcomes
which are statistically significant are more likely to be
published, with estimated odds for publication being two
to four times greater than those not reaching signifi-
cance [6]. The distorted presentation of study outcomes
gives rise to a potential over- or underestimation of
treatment effects or harms [2–4, 7].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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when results are meta-analysed and included in systematic
reviews [8]. In the ORBIT study, Kirkham et al. analysed
the prevalence of ORB within a cohort of Cochrane system-
atic reviews and reported that 34 % of Cochrane reviews in-
cluded one or more trials with a high suspicion for ORB in
its analysis [2]. In an exploratory sensitivity analysis of
Cochrane reviews with a single meta-analysis of the pri-
mary outcome, close to one fifth of those which reported
statistically significant results became non-significant once
adjusted for the presence of ORB in its primary studies [2].
In addition, almost one quarter (23 %) of the results in this
subgroup with statistical significance would have exagger-
ated the treatment effect by 20 % or more [2].
The Cochrane Collaboration is an international net-
work of researchers, health practitioners and patient ad-
vocates, aiming to produce and publish credible and
accessible health information free from conflicts of inter-
est. Cochrane reviews are recognised globally as being
systematic reviews of the highest standard in evidence-
based health care [9]. For Cochrane systematic reviews,
the Methodological Expectations of Cochrane Interven-
tion Reviews (MECIR) standards have been developed to
ensure high-quality and consistent review development
and reporting [10]. All Cochrane reviews must include an
assessment of risk of bias [10]. Cochrane review authors
are strongly encouraged to approach this assessment in a
domain-based fashion by applying the Cochrane risk of
bias tool, which addresses several domains of bias (i.e. se-
quence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment, incomplete outcome data, selective reporting) for
each trial considered for inclusion [4]. Instructions for per-
forming the assessment of risk of bias are outlined in the
Cochrane Handbook for Systematic Reviews of Interven-
tions, including factors to consider when determining if a
domain should be judged as “low,” “high” or “unclear” risk
of bias [4]. Briefly, review authors are asked to make the
judgement and include a description of how it was made,
referencing a direct quote or describing the text from
which the judgement was concluded, and include a com-
ment supporting the judgement. For the SRB domain, the
handbook provides instruction for the assessment of select-
ive outcome reporting. It encourages review authors to
construct a table or “matrix” of trials with their reported
outcomes to better identify gaps in reported outcomes. Re-
view authors are also encouraged to compare a trial’s proto-
col or registry data to its final publication to assess for
discrepancies in outcome reporting and to contact trial au-
thors for unreported outcome data whenever possible [4].
It is expected that review authors incorporate their risk
of bias assessment into their final analysis. Judgement
about which bias domains have the greatest potential to
affect their particular review’s results is a criticalconsideration for the review author [4]. Strategies to ad-
dress the implications of the risk of bias include present-
ing multiple analyses of data accounting for different types
of bias (e.g. worst-case scenario analysis for missing pa-
tient data), restricting the primary analysis to those studies
only carrying a low (or unclear) risk of bias (e.g. sensitivity
analysis for blinded vs open label studies), or presenting
all studies accompanied by a detailed narrative discussion
of the risk of bias [4].
The consideration of the review authors, editors and
staff from Cochrane review groups (CRGs) regarding this
assessment of risk of bias is crucial for the publication
of reliable, balanced and objective systematic reviews.
Cochrane review authors, however, may not be reliably de-
tecting ORB within trials [2]. Under-recognition of ORB
has recently been demonstrated in a study evaluating 30
well-respected biomedical journals [11]. In this survey-
based analysis, half of responding journals indicated that
ORB was uncommonly or never detected in their journal’s
editorial procedures and 64 % of the journals had no
method at all in place for detecting ORB [11].
Gaining knowledge of the understanding of and appre-
ciation for SRB by Cochrane review groups and the
methods they implement to account for the effect of
SRB from primary studies in systematic reviews will help
inform how current methods may be improved.
The primary aim of this research was to identify the
practices of CRGs for minimising SRB in their system-
atic reviews. This includes identifying the instruction
provided by CRGs to their review authors to assess for
and address selective outcome reporting in the various
stages of a systematic review (its protocol, the final re-
view, and subsequent updates). In addition, the specific
methods of each of the CRGs for verifying the complete-
ness of the assessment of SRB would be determined. A
secondary component of the research was to explore
how fully CRGs believe their review authors understand
and appreciate SRB.
Methods
A cross-sectional survey with 21 questions (see Additional
file 1) was developed with questions pertaining to the
following seven themes:
(1) Instruction provided to authors regarding SRB
(2) Consideration for SRB in systematic review protocol
(3) Assessment of risk of SRB within the RCTs in a
systematic review
(4) Assessment of risk of SRB on the level of the
systematic review
(5) Assessment of risk of SRB in updates of systematic
reviews
(6) Importance of SRB to review authors
(7) General
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theme (assessment of risk of SRB within the RCTs in a
systematic review). The responses to more than half of
the questions were categorical, with the number of cat-
egories ranging from three to five. The option for free-
text (“other” or “sometimes”) responses, however, was
also available in almost all questions. The survey content
was piloted for relevance with two active members of
the Cochrane Bias Methods Group with knowledge of
systematic reviews and SRB. Thereafter, three scientists
with no Cochrane involvement piloted the survey with
regards to readability. The questions were further ad-
justed based on these individuals’ feedback, to ensure
relevance and clarity.
The survey was distributed to the 52 Cochrane review
groups who conduct reviews of clinical interventions ex-
cluding only the Methodology Review Group. The man-
aging and coordinating editor(s) in each group were
invited via email to participate in the survey. These edi-
tors could choose to respond themselves or delegate the re-
sponse of the survey to another group member. The
intended respondent was an individual regularly involved in
reviewing assessments of risk of bias in systematic reviews
or having sufficient knowledge of this process to accurately
represent the practices of the CRG as a whole. Consultation
between group members was encouraged so that the re-
sponses would capture group practices rather than individ-
ual variations. One survey per CRG was accepted.
Distribution of the survey began in December 2013,
and collection of survey submissions continued until
March 2014. Up to three reminder emails were sent at
approximately two-week intervals.
Data were collected and tabulated with no identifying
information via the FluidSurveys™ survey platform. De-
scriptive statistics were used to analyse survey responses.
Five authors independently assessed all survey submis-
sions, and a meeting was held to discuss the responses,
including open-ended questions, to identify important
issues and patterns. The final decision on issues and pat-
terns to discuss further was determined by consensus.
Ethical approval for the study was received from both
the Behavioural Research Ethics Board at the University
of British Columbia and the Fraser Health Services
Authority, Vancouver, Canada.
Results
Of the 52 CRGs invited to participate in the study, 42
provided responses (81 %). In the one instance where
two completed surveys were received from one group,
the submitting group members were contacted and
asked to clarify via a single survey submission. Open-
ended responses accounted for approximately one fifth
of all responses. The meeting of five authors to discuss
survey responses identified trends in the open responses.Any key issues or patterns that were identified in cat-
egorical and open survey questions will be discussed in
the categories below. Full results, including all open
responses, are available via Figshare (http://dx.doi.org/
10.6084/m9.figshare.1421975).
Instruction provided to authors regarding SRB
The majority of CRGs refer their review authors to the
Cochrane Handbook for instruction regarding determining
outcomes for analysis (86 % [36/42]), selecting trials for in-
clusion (78 % [33/42]) and conducting their assessment of
SRB (86 % [36/42]). There was also a trend for referring re-
view authors to group-specific instruction or guidelines.
Consideration for SRB in systematic review protocol
Almost all CRGs require a statement in their systematic
review protocols that the Cochrane risk of bias tool will
be applied to all included RCTs (88 % [37/42]). Only
38 % (16/42) require a description within the protocol of
how the assessment of the risk of SRB will be incorpo-
rated into the results and/or discussion of the review.
Assessment of risk of SRB within the RCTs in a
systematic review
Three quarters of CRGs stated that review authors are
responsible for performing assessments of risk of SRB
(76 % [32/42]). Editorial staff members also play a role
in performing SRB assessments, with managing editor
involvement reported in 50 % [21/42] of CRGs. Some
open responses indicated methodological and statistical
editors perform assessments of SRB.
Less than half of CRGs report they always review risk
of bias assessments in submitted systematic reviews
(48 % [20/42]). Nineteen percent (8/42) of CRGs report
never verifying risk of bias assessments for SRB specific-
ally or verifying only that the risk of bias tool is completed.
It appeared from open responses that risk of bias assess-
ments were more likely to be verified if the risk of bias
tool appeared to be filled out incorrectly by review au-
thors. CRGs reported a very wide range (from 0–100 %)
for the number of reviews with SRB assessments that re-
quire revision before publication. The most frequently re-
ported requirement for revision was the risk of bias tool
being incomplete or discrepant.
Fifty-seven percent (24/42) of CRGs do not require re-
view authors to seek out trial protocols as a step in per-
forming their risk of SRB assessment. The time required
to perform the search and lack of availability of proto-
cols were indicated as barriers to performing this task.
Additionally, 31 % (13/42) of CRGs do not require re-
view authors to attempt to contact trial authors regard-
ing the completeness of outcome data. In some cases,
this step was reported to be encouraged, but not re-
quired. The creation of a “matrix” of reported trial
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was only reported by 14 % of CRGs (6/42), though a few
additional groups indicated that data extraction forms or
other group-specific tables may be used for this purpose.
The incorporation of an assessment of the risk of SRB
into the results or discussion section of the systematic
review is required by 45 % (19/42) of CRGs. If CRGs re-
ported that the incorporation is “sometimes” required, it
was typically only if SRB had been identified within the
review but not when SRB assessments were done and
did not find evidence of SRB.
Assessment of risk of SRB on the level of the systematic
review
Fifty-two percent (22/42) of CRGs report consistently
assessing for the selective inclusion of RCTs in a final
systematic review (i.e. is the subset of data included
fully representative of available trial data?). The system-
atic review protocol is compared to the final review
for consistency in defined outcome analyses by 86 %
(36/42) of CRGs. Eighty-six percent (36/42) of CRGs
reported that if a discrepancy in a protocol-defined out-
come is recognised, a justification for the change is in-
cluded in the methods (or more specifically, the
“Differences between protocol and review”) section of
the systematic review.
Assessment of risk of SRB in updates of systematic reviews
Despite being considered a mandatory MECIR standard,
only three quarters (31/42) of CRGs reported insisting
that the Cochrane risk of bias tool be applied to all
RCTs included when performing an update of a system-
atic review. In several instances, it was reported that
only newly incorporated RCTs were subject to assess-
ment with the risk of bias tool.
Importance of SRB to review authors
CRGs were asked to classify their authors’ degree of un-
derstanding of the existence of SRB, the implications of
SRB, their competency in completing and motivation
for completing assessments of SRB (see Fig. 1). Authors
were perceived as having a greater degree of under-
standing of the existence of SRB than the implications of
SRB (45 vs 26 % had a moderate or large extent of un-
derstanding, respectively). Thirty-one percent of groups
reported their authors had a “little” degree of compe-
tency in performing SRB assessments. Only one CRG
rated their review authors as having a “large” degree of
motivation to complete SRB assessments.
When considering only those CRGs who reported that
they refer their review authors to the Cochrane Handbook
for instruction for assessing SRB, only 23 % (9/39) classi-
fied their review authors to be moderately to largely
competent in performing SRB assessments.General
Four of 42 CRGs reported having frequently contacted
the Cochrane Bias Methods Group for guidance in the
previous year. Over 60 % of CRGs report never having
contacted the Cochrane Bias Methods Group in
this time.Discussion
Our survey in full provides an abundance of informa-
tion. Many of the results identify issues regarding the ex-
tent to which SRB is recognised and appreciated by
CRGs. The focus of this discussion is on the issues for
which we could identify a possible course of action for
improvement.
The completeness of SRB assessments in systematic
reviews relies on a comprehensive evaluation of the
presence of bias in included RCTs. Despite the Cochrane
Handbook being the primary resource for CRGs for
instructing risk of bias assessments, its recommenda-
tions for evaluating SRB are implemented to a variable
extent by different groups.
An essential step in assessing SRB is searching for each
trial’s protocol and comparing the originally defined out-
comes with those in the final publication for complete-
ness. It is reasonable to hypothesise that, with 57 % of
CRGs not requiring that trial protocols be identified and
reviewed, this disparity contributes to frequent “unclear”
risk of bias assessments in the SRB domain. As time and
resources involved in protocol and trial registry searches
are identified barriers to completing the step, it would be
advantageous to increase the guidance in the Cochrane
Handbook regarding streamlining these searches. A
greater availability of trial protocols in the public domain
would also help alleviate this strain [12]. Fortunately, the
use of trial registries has increased since the introduction
of the first trial registry platform (i.e. ClinicalTrials.gov) in
2000, and the implementation of policies encouraging the
registration of trial design information prior to patient
enrolment by the International Committee of Medicine
Journal Editors (ICMJE) and the United States Food and
Drug Administration (US FDA) in 2005 [13] and 2007
respectively [14]. Given the important implications of SRB
and the existing resources to access many protocols, we
feel the protocol search is a step that should be mandatory
in all systematic reviews, despite its additional time
requirement.
The Cochrane Handbook recommends that authors of
trials be contacted in attempt to access all pre-specified
outcome data in the case of discrepancies [4], yet our
survey suggests almost one third of CRGs make no at-
tempt to do so. We also consider this step critical to
making an informed judgement regarding the bias risk
for SRB.
Fig. 1 Q20: How do you rate your review authors’ understanding of SRB?
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it is prudent to incorporate these findings into the re-
sults and discussion of the systematic review in the man-
ner defined in the review protocol. The incorporation of
these assessments was reported to be a mandatory step
before review publication by 45 % of CRGs. Some
groups indicated that a comment on SRB would be
made only if the bias was recognised to be present. Con-
sidering the potentially extensive implications of SRB on
the findings of any trial, we feel striving to provide as
much detail as possible around its presence or absence
should be a priority in all systematic reviews to max-
imally inform readers.
A lack of understanding and appreciation for the im-
plications of SRB, as well as how one may comprehen-
sively assess for it, may very well be the root of the
aforementioned issues. In a survey administered by
Savovic and colleagues, SRB was identified by Cochrane
review authors as being one of the most difficult types of
bias to analyse in risk of bias assessments [15]. Further,
our survey included a set of questions inquiring, in gen-
eral, how well-equipped each CRG believes their review
authors are in addressing SRB in their reviews. Only
24 % of groups consider their authors to be moderately
or largely capable of performing SRB assessments, which
suggests a perceived knowledge gap for the review au-
thors. Despite this, only 48 % of CRGs reported that as-
sessments of risk of SRB in their reviews are consistently
(“always”) verified before publication, suggesting this is a
discrepancy worth addressing.We feel the approach to addressing the SRB-related is-
sues recognised in our survey would require targeting
several steps in the systematic review process. We fully
acknowledge that our survey did not address the training
and skills of review authors directly and focused instead
on editorial staff. It remains prudent, however, to include
review authors in our proposed approach to minimise
the impact of SRB in systematic reviews.
We suggest starting from the beginning, during the
training of Cochrane review authors. We propose that
standard author training be structured in a way that in-
cludes a focused review of SRB, including a focus on its
implications and the precise steps for its proper assess-
ment. Education could also go beyond this initial train-
ing, with the introduction of online learning modules or
refresher courses for assessing risk of bias for both new
and more seasoned review authors.
For the assessment of risk of SRB itself, the steps out-
lined in the Cochrane Handbook should more consistently
be followed. Optimal mandatory steps would require edi-
torial staff to enforce the protocol or trial registry search
and the contact attempts with original trial authors. By
doing this, trial exclusion due to the lack of relevant out-
come data as a result of SRB could be minimised.
The handbook-described organisation of trials and
their reported outcomes in a matrix was identified to be
an underused strategy. One suggestion that may help re-
view authors take a systematic approach to assessing
SRB is by each CRG implementing a standardised
matrix-based data extraction form (Fig. 2). On this form,
Fig. 2 Proposed matrix-based data extraction form. (Adapted from Dwan et al. [16])
Fig. 3 Proposed algorithm for judging risk of selective reporting bias
in primary studies
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as described previously [4, 16] but would also document
both the protocol search and author contact attempts.
This would help ensure each of these steps is performed
and would make the subsequent justification for the risk
of bias assessment very transparent. The proposed matrix
form outlines actions that need to take place in a checklist
format. This format could increase clarity for review au-
thors and facilitate the editorial process for CRGs by pre-
senting the data in an intuitive and concise manner. This
would allow CRG editorial staff to quickly assess and
verify the work of the review authors in assessing SRB.
To help clarify the approach of review authors for mak-
ing final risk of bias judgements for SRB, we suggest an al-
gorithm that lays out each step in the process (Fig. 3). If
the protocol of an included study is not available, for ex-
ample, the ensuing step is to check trial registries to locate
outcome data. If no such data are found, an attempt to
contact study authors is made. If the protocol or initial
outcome data are provided, a comparison to final reported
outcomes is made and the consistency determines “high”
or “low” risk of SRB. If no response is received from the
study authors, an “unclear” judgement is selected.
In order to verify the quality of risk of bias assess-
ments for SRB in a given systematic review, a specified
member of editorial staff could be delegated to double-
check the primary work. This could be performed as a
random sample of a certain percentage, e.g. 10 %, of in-
cluded trials, as a means for quality assurance.
Strengths and limitations
The high survey response rate (81 %) is an important
strength of our study. Respondents were intended to be
CRG staff members or authors with personal involvementor familiarity of risk of bias assessment practices within
their group, with discussion amongst members encour-
aged. Collecting only a single survey submission from each
CRG, however, may limit the scope of the information
provided to an individual viewpoint rather than reflect the
practices of all authors. Additionally, the skill level of re-
view authors themselves for addressing SRB was not dir-
ectly assessed and instead was reported only as how it was
perceived by the survey respondent. This would be better
investigated in a secondary study questioning review
authors and sampling their reviews directly.
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questions may limit the interpretation of the full scope
of each response, but the option to elaborate with a
free-form response was used to minimise this. With any
survey, there is the possibility of misinterpretation of
the questions; piloting of our survey questions was per-
formed to lessen this potential. The scope of our survey
is limited to a single component of the Cochrane risk of
bias tool, which only represents a small portion of the
labours of writing and updating Cochrane reviews [15].
Future research is aimed at determining practices of
Cochrane review authors themselves for assessing SRB
within a sample of reviews, and also exploring other
bias domains.
Application
This study will be of relevance to Cochrane review and
methodology groups as well as non-Cochrane systematic
reviewers. It will also provide insight for future updates
to the Cochrane risk of bias tool and the Cochrane
Handbook. It is of importance to the Strengthening the
Reporting of Observational studies in Epidemiology
(STROBE) efforts [17], the use of the Prospective Regis-
tering of Systematic Reviews (PROSPERO) [18], the devel-
opment of core outcome sets for the Core Outcome
Measures in Effectiveness Trials (COMET) Initiative [19],
the use of the Consolidated Standards of Reporting Trials
(CONSORT) Statement [20], and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) Statement [21].
Conclusions
Our study indicates that the recommendations in the
Cochrane Handbook for assessing SRB are variably
enforced by CRGs. The majority of CRGs do not consider
their review authors sufficiently competent to assess for
SRB, yet risk of bias assessments are not consistently veri-
fied by editors before publication. The implications of SRB
may not be fully appreciated by all CRGs, and resolving
the identified issues may require a multi-faceted approach
targeting several steps in the systematic review process.
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